Variables | HIV mono-infected | HIV/HCV co-infected | P-value |
---|---|---|---|
N = 2333 | N = 1622 | ||
Sex, n(%) | Â | Â | Â |
 Female | 269 (37) | 466 (63) | < 0.0001 |
 Male | 2064 (64) | 1156 (36) |  |
Age at ART initiation (years), n(%) | Â | Â | Â |
 < 30 | 304 (63) | 177 (37) | < 0.0001 |
 30–39 | 726 (60) | 490 (40) |  |
 40–49 | 780 (54%) | 661 (46%) |  |
 ≥ 50 | 523 (64%) | 294 (36%) |  |
Risk, n(%) | Â | Â | Â |
 MSM | 1144 (88) | 150 (12) | < 0.0001 |
 IDU | 122 (9) | 1176 (91) |  |
 MSM/IDU | 122 (39) | 187 (61) |  |
 Other | 514 (88) | 67 (12) |  |
 Unknown | 431 (91) | 42 (9) |  |
ART era, n(%) | Â | Â | Â |
 2000–2003 | 403 (51) | 394 (49) | < 0.0001 |
 2004–2007 | 628 (54) | 525 (46) |  |
 2008–2011 | 1001 (63) | 598 (37) |  |
 2012–2013 | 301 (74) | 105 (26) |  |
Baseline CD4 cell count (cells/mm3), n(%) | Â | Â | Â |
 < 50 | 276 (58) | 198 (42) | < 0.0001 |
 50–199 | 640 (50) | 645 (50) |  |
 200–349 | 746 (60) | 492 (40) |  |
 ≥ 350 | 671 (70) | 287 (30) |  |
Last CD4 cell count (cells/mm3), n(%) | Â | Â | Â |
 < 50 | 40 (33) | 81 (67) | < 0.0001 |
 50–199 | 101 (31) | 228 (69) |  |
 200–349 | 232 (46) | 277 (54) |  |
 ≥ 350 | 1732 (67) | 864 (33) |  |
 Unknown | 228 (57) | 172 (43) |  |
ART Adherence (first six months), n(%) | Â | Â | Â |
 ≥ 95% | 1987 (64) | 1097 (36) | < 0.0001 |
 80–94% | 100 (48) | 108 (52) |  |
 40–79% | 182 (41) | 263 (59) |  |
 < 40% | 64 (29) | 154 (71) |  |
ART Adherence (last six months), n(%) | Â | Â | Â |
 ≥ 95% | 1821 (65) | 960 (35) | < 0.0001 |
 80–94% | 122 (47) | 140 (53) |  |
 40–79% | 224 (45) | 277 (55) |  |
 < 40% | 166 (40) | 245 (60) |  |
Number of comorbidities at baseline, n(%) | Â | Â | Â |
 0 | 1067 (79) | 290 (21) | < 0.0001 |
 1 | 745 (57) | 562 (43) |  |
 2 | 331 (46) | 394 (54) |  |
 ≥3 | 190 (34) | 376 (66) |  |
Number of comorbidities at the end of follow-up, n(%) | Â | Â | Â |
 0 | 961 (82) | 215 (18) | <0.0001 |
 1 | 687 (62) | 421 (38) |  |
 2 | 333 (47) | 382 (53) |  |
 ≥3 | 352 (37) | 604 (63) |  |
Initial ART regimen, n(%) | Â | Â | Â |
 NNRTI | 1098 (58) | 797 (42) | 0.2109 |
 bPI | 1235 (60) | 825 (40) |  |
Total healthcare-related visits, median (Q1-Q3) | 83 (43–150) | 143 (68–278) | < 0.0001 |
Baseline viral load (log10 copies/mL), median (Q1-Q3) | 4.92 (4.42–5.00) | 4.87 (4.35–5.00) | 0.0048 |
Last viral load (log10 copies/mL), median (Q1-Q3) | 1.69 (1.69–1.69) | 1.69 (1.69–1.98) | < 0.0001 |
Follow-up time (years), median (Q1-Q3) | 4.95 (2.50–7.91) | 5.30 (2.99–8.31) | 0.0038 |